Is the role of intravesical bacillus Calmette-Guérin in non-muscle-invasive bladder cancer changing?

BJU International

Volumn 105, Issue SUPPL. 2, 2010, Pages 8-13

  Ayres, Benjamin E ^a   Griffiths, T R Leyshon ^b   Persad, Raj A ^c  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; ISONIAZID; MITOMYCIN C; OFLOXACIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; HEMATURIA; HUMAN; MAINTENANCE THERAPY; MALAISE; MELANOMA; MONOTHERAPY; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 75149142896     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09151.x     Document Type: Review

References (45)

1. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. Eur Urol 2008 54: 303 314
2. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007 178: 2314 2330
3. British Association of Urological Surgeons/British Uro-oncology Group MDT (Multidisciplinary Team). Guidance for Managing Bladder Cancer. BAUS/BUG 2007. Available at: http://www.bauslibrary.co.uk/PDFS/BSONC/ MDT%20guidance%20for%20bladder%20cancer.pdf. Accessed November 2009
4. National Comprehensive Cancer Network. Bladder cancer, V.l.2010. Available at: http://www.nccn.org. Accessed November 2009
5. Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients and seven EORTC trials. Eur Urol 2006 49: 466 477
6. Griffiths TRL, Mellon JK. Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J 2004 80: 320 327
7. Lamm D, Colombel M, Persad R et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008 7: 651 666
8. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976 116: 180 183
9. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980 124: 38 40
10. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of Ta T1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996 156: 1934 1941
11. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003 169: 90 5
12. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004 93: 485 490
13. Malmström P-U, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009 56: 247 256
14. Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 2003 26: 402 407
15. Sylvester RJ, van der Meijden Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002 168: 1964 1970
16. Böhle A, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004 63: 682 687
17. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005 174: 86 91
18. Herr HW. Is maintenance bacillus Calmette-Guérin really necessary? J Urol 2008 54: 971 973
19. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000 163: 1124 1129
20. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: How much is enough? Cancer 2008 113: 710 716
21. Badalament RA, Herr HW, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical BCG therapy of superficial bladder cancer. J Clin Oncol 1987 5: 441 449
22. Palou J, Laguna P, Millan-Rodriquez F et al. Control group and maintenance treatment with BCG for carcinoma in situ and/or high grade bladder tumours. J Urol 2001 165: 1488 1491
23. Hudson MA, Ratliff TL, Gillen DP et al. Single course versus maintenance BCG therapy for superficial bladder tumors: a prospective randomized trial. J Urol 1987 138: 295 298
24. Akaza H, Hinotsu S, Aso Y et al. BCG treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995 75: 552 559
25. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003 44: 429 434 (Pubitemid 37185667)
26. Martínez-Piñeiro JA, Flores N, Isorna S et al. for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002 89: 671 680
27. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E et al. Club Urologico Espanol de Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005 174: 1242 1247
28. Ojea A, Nogueira JL, Solsona E et al. CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C. Eur Urol 2007 52: 1398 1406
29. European Organisation for Research and Treatment of Cancer. EORTC 30962. Available at: http://www.eortc.be/protoc/details.asp?protocol=30962. Accessed November 2009
30. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001 166: 476 481
31. Colombel M, Saint F, Chopin D, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006 176: 935 939
32. Buckley R, Rischmann P, Colombel M et al. Prophylactic ofloxacin to improve tolerance of BCG instillations: two-year results of a prospective double-blind placebo-controlled study in patients with bladder cancer. Urology 2006 68 (Suppl. 1 42
33. Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009 56: 260 265
34. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007 52: 1123 1130
35. Sylvester RJ, Brausi MA, Hoeltl W et al. Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacillus Calmette-Guérin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladder. Eur Urol Suppl 2008 7: 298
36. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2007 100: 33 6
37. Kulkarni GS, Hakenberg OW, Gschwend JE et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2009 Sep 1.
38. [Epub ahead of print HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006 97: 1194 1198
39. Griffiths TR, Charlton M, Neal DE, Powell H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002 167: 2408 2412
40. Kamat AM, Dinney CP, Gee JR et al. Micropapillary bladder cancer: a review of the University of Texas M.D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007 110: 62 7
41. Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003 170: 777 782
42. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006 7: 43 51
43. Colombo R, Da Pozza LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996 155: 1227 1232
44. Colombo R, Da Pozza LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003 21: 4270 4276
45. Nativ O, Witjes JA, Hendricksen K et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009 182: 1313 1317